Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Autoimmune diseases
Biomarkers
Humans
Analyses multidimensionnelles
Cytokines
Antiphospholipid syndrome
Autoantibodies
Prognosis
Adjudication
Machine learning
Anti-drug antibodies
AAV vector
Antisynthétase
Adeno-associated virus vector
Acid-alpha-glucosidase
Male
Biomarker
Pharmacology
Antisynthetase syndrome
Aldosterone
Biopsy
Anémie hémolytique
Polymyositis
AAV
Inflammation
AAV antibody
Dependovirus/genetics/immunology
Myositis and muscle disease
Gene therapy
Amyotrophic lateral sclerosis
Active
Anti-Mi2
Adverse drug reactions
Amyotrophy
Anti-MDA5 autoantibodies
AAV vectors
Data integration
Antisynthetase
Anti-agalsidase antibodies
Antibodies
AAV humoral immunity
Anti-IgE IgG
Deep immune profiling
IBM
Myopathy
Cardio-oncology
Anti-synthetase syndrome
Antibody responses
Anticorps spécifique des myosites
Anti‐mitochondrial antibodies
Bioelectrical impedance analysis
Immunotherapy
Adult
Auto-immunité
B-lymphocyte
Aged
Adolescence
Anticorps anti-agalsidase
Inborn errors of metabolism
Sphingosine-1-phosphate
Myositis
Autoimmunity
Lysosomal storage diseases
Aldostérone
Arthritis
Idiopathic inflammatory myopathies
Auto‐antibodies
Agalsidase
Dermatomyositis
Auto-antibodies
Interstitial lung disease
Assisted communication devices
Acute Kidney Injury/epidemiology/etiology
Middle Aged
B cell homeostasis
Inflammatory myopathy
Case reports
DM
Skeletal muscle
Muscle
Systems biology
Biomarqueurs
Myocarditis
Animals
IMNM
COVID-19
Anti-interleukin-6
Cancer
Mass cytometry
Immune checkpoint inhibitors
Inclusion body myositis
Female
Multidisciplinarity
Adeno-associated virus
Interferon
Adeno-associated vector
Autoantibody
Outcome measures
Fabry disease
Abnormal movement